| scholarly article | Q13442814 |
| P50 | author | Andrea B. Troxel | Q43414494 |
| P2093 | author name string | Joerg Albrecht | |
| Victoria P Werth | |||
| Joyce Okawa | |||
| Lynne Taylor | |||
| Sam Dulay | |||
| Zuleika L Bonilla-Martinez | |||
| P2860 | cites work | Assessment of skin erythema by eye, laser Doppler flowmeter, spectroradiometer, two-channel erythema meter and Minolta chroma meter | Q36770355 |
| The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus | Q37591255 | ||
| Quality of life and disease severity in a cutaneous lupus erythematosus pilot study | Q39316700 | ||
| Clinically important changes in acute pain outcome measures: a validation study | Q39395429 | ||
| Measuring change over time: assessing the usefulness of evaluative instruments. | Q52608136 | ||
| Measuring the activity of the disease in patients with cutaneous lupus erythematosus | Q61508690 | ||
| Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain | Q80476028 | ||
| P433 | issue | 2 | |
| P921 | main subject | cutaneous lupus erythematosus | Q18553226 |
| P304 | page(s) | 173-180 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | Archives of Dermatology | Q15749524 |
| P1476 | title | The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus | |
| P478 | volume | 144 |
| Q64043005 | Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations |
| Q33542751 | B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data |
| Q37591252 | Characterization of clinical photosensitivity in cutaneous lupus erythematosus |
| Q38685402 | Classifying discoid lupus erythematosus: background, gaps, and difficulties |
| Q38793272 | Classifying discoid lupus erythematosus: background, gaps, and difficulties |
| Q36690483 | Clinical characteristics of cutaneous lupus erythematosus. |
| Q34561606 | Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument |
| Q92464993 | Cutaneous lupus erythematosus: A review of the literature |
| Q34267149 | Data quality challenges in systemic lupus erythematosus trials: how can this be optimized? |
| Q36994240 | Development of outcome measures for autoimmune dermatoses |
| Q35764310 | Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus |
| Q55007548 | Disease severity and prophylactic measures in patients with cutaneous lupus erythematosus: results of a worldwide questionnaire-based study. |
| Q35289684 | Efficacy of Intravenous Immunoglobulin Monotherapy in Patients with Cutaneous Lupus Erythematosus: Results of Proof-of-Concept Study |
| Q51541832 | Evaluation of disease activity and damage in different subtypes of cutaneous lupus erythematosus using the CLASI. |
| Q47960652 | Evaluation of the quality of life of lupus erythematosus patients with cutaneous lesions in Japan |
| Q34188885 | Expression of interleukin-17 is correlated with interferon-α expression in cutaneous lesions of lupus erythematosus. |
| Q38888712 | Immunogenetics of cutaneous lupus erythematosus |
| Q51150943 | Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. |
| Q35836605 | Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare |
| Q38731966 | Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience |
| Q52320880 | Lupus community panel proposals for optimising clinical trials: 2018. |
| Q41558860 | Measurement of disease severity in cutaneous autoimmune diseases |
| Q33781378 | Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument |
| Q89406047 | Natural history of disease activity and damage in patients with cutaneous lupus erythematosus |
| Q57927779 | Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study |
| Q35353447 | Prevalence of self-report photosensitivity in cutaneous lupus erythematosus |
| Q28079267 | Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity |
| Q39316700 | Quality of life and disease severity in a cutaneous lupus erythematosus pilot study |
| Q34810851 | Quality of life in cutaneous lupus erythematosus |
| Q47760514 | Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus |
| Q53105319 | Relationship between health-related quality of life and SLE activity and damage in children over time. |
| Q35764302 | Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis |
| Q37620086 | Rheumatic manifestations of skin disease |
| Q89868359 | Robust measurement of clinical improvement in patients with cutaneous lupus erythematosus |
| Q42485930 | The cutaneous lupus disease activity and severity index as a validated outcome measure for cutaneous lupus erythematosus: comment on the article by Stamm et al. |
| Q36932364 | The impact of skin damage due to cutaneous lupus on quality of life |
| Q39076011 | The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists |
| Q38100735 | Top 10 things to know about lupus activity measures |
| Q36230971 | Treatment of lupus erythematosus of the eyelids with pulsed dye laser |
| Q34605279 | Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus |
| Q36932360 | Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change |
| Q59797303 | Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkindex27 for use in childhood-onset systemic lupus erythematosus |
| Q38793267 | Validation studies of outcome measures in pemphigus |
| Q81753277 | [Dermatological symptoms in rheumatology] |
Search more.